Provectus Biopharmaceuticals, Inc.
PVCT
$0.0923
-$0.0046-4.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 617.10K | 723.90K | 683.90K | 590.70K | 557.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 617.10K | 723.90K | 683.90K | 590.70K | 557.60K |
| Cost of Revenue | -9.20K | 99.90K | 37.10K | -8.10K | -15.70K |
| Gross Profit | 626.50K | 624.10K | 646.80K | 598.80K | 573.30K |
| SG&A Expenses | 2.61M | 1.08M | 990.60K | 930.50K | 1.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.56M | 2.90M | 2.74M | 2.64M | 3.06M |
| Operating Income | -3.95M | -2.17M | -2.06M | -2.05M | -2.50M |
| Income Before Tax | -4.76M | -3.03M | -2.79M | -2.78M | -3.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.76 | -3.03 | -2.79 | -2.78 | -3.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.76M | -3.03M | -2.79M | -2.78M | -3.10M |
| EBIT | -3.95M | -2.17M | -2.06M | -2.05M | -2.50M |
| EBITDA | -3.94M | -2.16M | -2.05M | -2.04M | -2.49M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.68B | 1.68B | 1.68B | 1.68B | 1.68B |
| Average Diluted Shares Outstanding | 1.68B | 1.68B | 1.68B | 1.68B | 1.68B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |